

Mattia Trunfio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1755546/publications.pdf>

Version: 2024-02-01

46
papers

531
citations

687220

13
h-index

752573

20
g-index

47
all docs

47
docs citations

47
times ranked

867
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnostic SARS-CoV-2 Cycle Threshold Value Predicts Disease Severity, Survival, and Six-Month Sequelae in COVID-19 Symptomatic Patients. <i>Viruses</i> , 2021, 13, 281.	1.5	51
2	Co-infection with other respiratory pathogens in COVID-19 patients. <i>Clinical Microbiology and Infection</i> , 2021, 27, 297-298.	2.8	46
3	Bacterial coinfections in dengue virus disease: what we know and what is still obscure about an emerging concern. <i>Infection</i> , 2017, 45, 1-10.	2.3	36
4	The role of antirheumatics in patients with COVID-19. <i>Lancet Rheumatology</i> , The, 2021, 3, e447-e459.	2.2	36
5	Risk for SARS-CoV-2 Infection in Healthcare Workers, Turin, Italy. <i>Emerging Infectious Diseases</i> , 2021, 27, 303-305.	2.0	28
6	A review of the potential mechanisms of neuronal toxicity associated with antiretroviral drugs. <i>Journal of NeuroVirology</i> , 2020, 26, 642-651.	1.0	21
7	Anti-Xa monitoring improves low-molecular-weight heparin effectiveness in patients with SARS-CoV-2 infection. <i>Thrombosis Research</i> , 2020, 196, 432-434.	0.8	20
8	Diagnostic accuracy of new and old cognitive screening tools for HIV-associated neurocognitive disorders. <i>HIV Medicine</i> , 2018, 19, 455-464.	1.0	19
9	Cerebrospinal fluid HIV-1 escape according to different thresholds and underlying comorbidities. <i>Aids</i> , 2019, 33, 759-762.	1.0	19
10	Lower dolutegravir plasma concentrations in HIV-positive patients receiving valproic acid. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 826-827.	1.3	18
11	On the SARS-CoV-2 "Variolation Hypothesis": No Association Between Viral Load of Index Cases and COVID-19 Severity of Secondary Cases. <i>Frontiers in Microbiology</i> , 2021, 12, 646679.	1.5	17
12	Factors Associated with Severe COVID-19 and Post-Acute COVID-19 Syndrome in a Cohort of People Living with HIV on Antiretroviral Treatment and with Undetectable HIV RNA. <i>Viruses</i> , 2022, 14, 493.	1.5	17
13	CNS-Targeted Antiretroviral Strategies: When Are They Needed and What to Choose. <i>Current HIV/AIDS Reports</i> , 2018, 15, 84-91.	1.1	16
14	What can characterization of cerebrospinal fluid escape populations teach us about viral reservoirs in the central nervous system?. <i>Aids</i> , 2019, 33, S171-S179.	1.0	15
15	Alzheimer's Dementia in People Living With HIV. <i>Neurology: Clinical Practice</i> , 2021, 11, 10.1212/CPJ.0000000000001060.	0.8	15
16	Cerebrospinal Fluid Viral Load Across the Spectrum of Untreated Human Immunodeficiency Virus Type 1 (HIV-1) Infection: A Cross-Sectional Multicenter Study. <i>Clinical Infectious Diseases</i> , 2022, 75, 493-502.	2.9	15
17	Older Age is Associated with Higher Dolutegravir Exposure in Plasma and Cerebrospinal Fluid of People Living with HIV. <i>Clinical Pharmacokinetics</i> , 2021, 60, 103-109.	1.6	12
18	Blood-Brain Barrier Impairment in Patients Living with HIV: Predictors and Associated Biomarkers. <i>Diagnostics</i> , 2021, 11, 867.	1.3	11

#	ARTICLE	IF	CITATIONS
19	Lowering SARS-CoV-2 viral load might affect transmission but not disease severity in secondary cases. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 914-915.	4.6	10
20	Determinants of SARS-CoV-2 Contagiousness in Household Contacts of Symptomatic Adult Index Cases. <i>Frontiers in Microbiology</i> , 2022, 13, 829393.	1.5	9
21	The symptomatology of cerebrospinal fluid HIV RNA escape: a large case-series. <i>Aids</i> , 2021, 35, 2341-2346.	1.0	8
22	Dual antiretroviral therapies are effective and safe regimens in the central nervous system of neurologically symptomatic people living with HIV. <i>Aids</i> , 2020, 34, 1899-1906.	1.0	7
23	Seroprevalence of SARS-CoV-2 Among Workers in Northern Italy. <i>Annals of Work Exposures and Health</i> , 2022, 66, 224-232.	0.6	7
24	The impact of age on antiretroviral drug pharmacokinetics in the treatment of adults living with HIV. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021, 17, 665-676.	1.5	7
25	Low cerebrospinal fluid Amyloid- β 42 in patients with tuberculous meningitis. <i>BMC Neurology</i> , 2021, 21, 449.	0.8	7
26	Clinical Phenotype and Contagiousness of Early Breakthrough SARS-CoV-2 Infections after BNT162b2 COVID-19 mRNA Vaccine: A Parallel Cohort Study in Healthcare Workers. <i>Vaccines</i> , 2021, 9, 1377.	2.1	6
27	Correlations between cerebrospinal fluid biomarkers, neurocognitive tests, and resting-state electroencephalography (rsEEG) in patients with HIV-associated neurocognitive disorders. <i>Journal of NeuroVirology</i> , 2022, 28, 226-235.	1.0	6
28	Patterns of Cerebrospinal Fluid Alzheimer's Dementia Biomarkers in People Living with HIV: Cross-Sectional Study on Associated Factors According to Viral Control, Neurological Confounders and Neurocognition. <i>Viruses</i> , 2022, 14, 753.	1.5	6
29	Clinical and viro-immunological correlates of HIV associated neurocognitive disorders (HAND) in a cohort of antiretroviral-naïve HIV-infected patients. <i>Aids</i> , 2017, 31, 311-314.	1.0	5
30	Symptomatic cerebrospinal fluid HIV-1 escape with no resistance-associated mutations following low-level plasma viremia. <i>Journal of NeuroVirology</i> , 2018, 24, 132-136.	1.0	5
31	Medication burden and clustering in people living with HIV undergoing therapeutic drug monitoring. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4432-4438.	1.1	4
32	Screening Accuracy of Mini Addenbrooke's Cognitive Examination Test for HIV-Associated Neurocognitive Disorders in People Ageing with HIV. <i>AIDS and Behavior</i> , 2022, 26, 2203-2211.	1.4	4
33	Undetectable antimicrobial plasma concentrations in an HIV-positive patient with protein-losing enteropathy and chylothorax during <i>Mycobacterium genavense</i> and <i>Leishmania</i> abdominal infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 546-548.	1.3	3
34	Peripheral and cerebrospinal fluid immune activation and inflammation in chronically HIV-infected patients before and after virally suppressive combination antiretroviral therapy (cART). <i>Journal of NeuroVirology</i> , 2018, 24, 679-694.	1.0	3
35	Early low-molecular-weight heparin administration is associated with shorter time to SARS-CoV-2 swab negativity. <i>Antiviral Therapy</i> , 2021, 25, 327-333.	0.6	3
36	Malignant Melanoma in People Living with HIV/AIDS: Can We Know More, Can We Do Better?. <i>AIDS Reviews</i> , 2019, 21, 65-75.	0.5	3

#	ARTICLE	IF	CITATIONS
37	The "milky way" galaxy of HIV-related central nervous system immune reaction syndromes. <i>Journal of NeuroVirology</i> , 2019, 25, 887-892.	1.0	2
38	HIV-1 detection in the olfactory mucosa of HIV-1-infected participants. <i>Aids</i> , 2019, 33, 665-674.	1.0	2
39	The Manifesto of Pharmacoenosis: Merging HIV Pharmacology into Pathocoenosis and Syndemics in Developing Countries. <i>Microorganisms</i> , 2021, 9, 1648.	1.6	2
40	Case Report: Atypical Cutaneous Presentation of Human T-cell Lymphotropic Virus Type 1-Related Adult T-cell Lymphoma. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, , .	0.6	2
41	Norepinephrine may improve survival of septic shock patients in a low-resource setting: a proof-of-concept study on feasibility and efficacy outside the Intensive Care Unit. <i>Pathogens and Global Health</i> , 2022, 116, 389-394.	1.0	2
42	Antiviral activity of maraviroc plus mirtazapine in a low-risk HIV-negative patient with progressive multifocal leukoencephalopathy. <i>Infezioni in Medicina</i> , 2018, 26, 160-163.	0.7	2
43	Concurrent and Subsequent Co-Infections of <i>Clostridioides difficile</i> Colitis in the Era of Gut Microbiota and Expanding Treatment Options. <i>Microorganisms</i> , 2022, 10, 1275.	1.6	2
44	JC virus DNA in cerebrospinal fluid: insight into clinical significance. <i>Diagnostic Microbiology and Infectious Disease</i> , 2020, 97, 115017.	0.8	1
45	Ultrasonography of an Oral Cavity Onchocercidae Nodule. <i>American Journal of Tropical Medicine and Hygiene</i> , 2018, 98, 645-646.	0.6	1
46	Use of self-prescribed medications and complementary medicines in a cohort of women with HIV. <i>Aids</i> , 2022, 36, 617-619.	1.0	0